Cancer has no borders. Neither do we.

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

BeiGene News

May 17, 2022

BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland

Read more

May 12, 2022

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

Read more

May 5, 2022

BeiGene Reports First Quarter 2022 Financial Results

Read more

May 4, 2022

BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Read more

April 29, 2022

BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

Read more

April 28, 2022

BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia

Read more